Gallant[™] Dual Chamber ICD

Product Highlights

- Bluetooth[®] Low Energy (LE) communication enabling smartphone connectivity through data encryption
- 40J delivered energy safety shock option for enhanced safety margin
- DeFT Response[™] technology offers noninvasive programming options to optimize rescue therapy to each patient's unique physiology and changing conditions
- VF Therapy Assurance decreases time to treatment for arrhythmias in patients who are likely to be hemodynamically unstable
- Antitachycardia pacing (ATP) while charging and prior to charging in the VF zone extends the programming options for terminating tachyarrhythmias without a high-voltage shock
- ShockGuard[™] technology with DecisionTx[™] programming designed to reduce inappropriate therapy and minimize the need for programming adjustments at implant
 - SecureSense[™] RV lead noise discrimination algorithm detects sustained lead noise and records short bursts of oversensing that would otherwise go unnoticed or potentially lead to one or more inappropriate shocks
 - Far Field MD[™] morphology discrimination and chamber onset discrimination enhance SVT and VT discrimination for reduced inappropriate therapies

• Sense*Ability*[™] sensing algorithm feature provides the flexibility to fine-tune programming around T-wave oversensing without decreasing sensitivity

Abboatt

• DynamicTx[™] over-current detection algorithm automatically changes shock configurations to ensure delivery of high-voltage therapy when high current is detected

MR

Compatible with myMerlinPulse[™] app

- MRI-Ready device tested in combination with MR Conditional leads for full-body scans using a 1.5T or 3T (Tesla) field strength MRI Scanner*
- Cold can programmability provides an additional RV-SVC shock configuration to decouple the can from the shocking vector parameters
- The CorVue[™] thoracic impedance feature measures transthoracic impedance changes over time to provide additional insight into the patient's heart failure condition
- Premature Atrial Contraction (PAC) Response to avoid pacing the atrium in a vulnerable zone
- Physiologic rate responsive AV Delay and PVARP
- Dual patient notification: audio notification through the device and visual notification via myMerlinPulse app

Ordering Information

Contents: Cardiac Pulse Generator

MODEL NUMBER	DIMENSIONS (L × W × H) (MM)	WEIGHT (G)	VOLUME (CC)	CONNECTOR DEFIBRILLATION	CONNECTOR SENSE/PACE
CDDRA500T	73 × 51 × 12	72	35	DF-1	IS-1

*See MRI Scan Parameters in MRI-Ready Systems Manual.



PARAMETER SPECIFICATIONS		
Model	CDDRA500T	
Гelemetry	Bluetooth [*] LE Communication	
Delivered/Stored Energy	40/45 J	
Volume	35 cc	
Weight	72 g	
Size	73 × 51 × 12 mm	
Defibrillation Lead Connection	DF-1	
Atrial Sense/Pace Lead Connection	IS-1 in-line bipolar	
Ventricular Sense/Pace Lead Connection	IS-1 in-line bipolar	
High-Voltage Can	Electrically active titanium can	
Parameter	Settings	
AF Management		
AF Suppression [™] Pacing No. of Overdrive Pacing Cycles Maximum AF Suppression Rate	On; Off 15-40 80-150 bpm	
Sensing/Detection		
Sense <i>A bility</i> [™] Sensing Algorithm	Automatic Sensitivity Control adjustment for atrial and ventricular events	
Low Frequency Attenuation	On; Off	
Threshold Start	Post-Sensed: 50; 62.5; 75; 100% Post-Paced, Atrial: 0.2-3.0 mV Post-Paced, Ventricular: Auto, 0.2-3.0 mV	
Decay Delay	Post-Sensed: 0-220 ms Post-Paced, Atrial: 0-220 ms Post-Paced, Ventricular: Auto, 0-220 ms	
Ventricular Sense Refractory	125; 157 ms	
Detection Zones	3 zone programming – 1 zone; 2 zones; or 3 zones (VT-1; VT-2; VF)	
SVT Discriminators	AV Rate Branch; Arrhythmia Onset (Chamber Onset or Sudden Onset); Interval Stability; AV Association; Morphology Discrimination (Far Field MD [™] Morphology Discrimination or Original MD) with Automatic Template Update	
Monitor Mode	Detection; Discrimination; Diagnostics; No therapy delivery (VT or VT-1 zone)	
Discrimination Modes	On; Passive; Off	
SVT Upper Limit	150-240 bpm	
SVT Discrimination Timeout	20s-60 min; Off	
Reconfirmation	Continuous sensing during charging	
SecureSense [™] RV Lead Noise Discrimination Algorithm	On; On with Timeout; Passive; Off	
/F Therapy Assurance	On; Off	
Antitachycardia Pacing Therapy		
ATP Configurations	Ramp; Burst; Scan; 1 or 2 schemes per VT zone	
ATP in VF Zone	ATP While Charging; ATP Prior to Charging; Off	
ATP Upper Rate Cutoff	150-300 bpm	
urst Cycle Length	Adaptive (50%-100%); Fixed (200-550 ms)	
Iin. Burst Cycle Length	150-400 ms	
Readaptive	On; Off	
Jumber of Bursts	1-15	
Number of Stimuli	2-20	
Add Stimuli per Burst	2-20 On; Off	
ATP Pulse Amplitude	7.5 V independent from Bradycardia and Post-Therapy Pacing	
	1.0 or 1.5 ms independently programmable from bradycardia and post-therapy pacing	

High-Voltage Therapy		
DynamicTx [™] Over-current Detection Algorithm	On; Off	
DeFT Response™ Technology	Programmable pulse width for P1/P2 and tilt	
High-Voltage Output Mode	Fixed Pulse Width; Fixed Tilt	
Waveform	Biphasic; Monophasic	
RV Polarity	Cathode (-); Anode (+)	
Electrode Configuration	RV to Can; RV to SVC/Can; RV to SVC	
Bradycardia Pacing		
Permanent Modes	Off; DDD(R); DDI(R); VVI(R); AAI(R)	
Temporary Modes	Off; DDD; DDI; VVI; AAI; AAT; DOO; VOO; AOO	
Activity Sensor	On; Passive; Off	
Programmable Rate and Delay Parameters	Base Rate (bpm); Rest Rate (bpm); Maximum Tracking Rate (bpm); Maximum Sensor Rate (bpm); Paced AV Delay (ms); Sensed AV Delay (ms); Rate Responsive AV Delay; Hysteresis Rate (bpm); Rate Hysteresis with Search	
Pulse Amplitude	0.25-7.5 V	
Pulse Width	0.05 ms; 0.1-1.5 ms	
Ventricular AutoCapture [™] Pacing System	On; Off	
ACap [™] Confirm Feature	On; Monitor; Off	
QuickOpt [™] Timing Cycle Optimization	Sensed/Paced AV delay	
Auto Mode Switch (AMS)	DDI(R); VVI(R); Off	
Atrial Tachycardia Detection Rate	110-300 bpm	
AMS Base Rate	40; 45; 135 bpm	
Rate Responsive PVARP	Low; Medium; High; Off	
Rate Responsive V Pace Refractory	On; Off	
PAC Response	On; Off	
PAC Response Interval	200-400 ms	
PMT Detection/Termination	Atrial Pace; Passive; Off	
Ventricular Intrinsic Preference (VIP™)	On (50-200 ms); Off	
Post-Therapy Pacing (Independently	programmable from Bradycardia and ATP)	
Post-Shock Pacing Mode	AAI; VVI; DDI; DDD; Off	
Post-Shock Base Rate	30-100 bpm	
Post-Shock Pacing Duration	0.5; 1; 2.5; 5; 7.5; or 10 min; Off	
Device Testing/Induction Methods		
DC Fibber [™] Induction Method Pulse Duration	0.5-5.0 sec	
Burst Fibber Cycle Length	20-100 ms	
Noninvasive Programmed Stimulation (NIPS)	2-25 stimuli with up to 3 extra stimuli	

Product Specifications

Patient Notifiers

(On; Off)

Programmable Notifiers

Device Parameter Reset Entry into Backup VVI Mode

Auditory Duration Number of Audio alerts per Notification Number of Notifications Time Between Notifications

ns	
	BatteryAssurance [™] alert; Possible HV circuit damage; HV charge timeout; Long charge time for Capacitor Maintenance; Device at ERI; Atrial pacing lead impedance out of range. Ventricular pacing lead impedance out of range; High-voltage lead impedance out of range; AT/AF Episode duration; AT/AF Burden; High ventricular rate during AT/AF; SecureSense [™] lead noise detection; Non-sustained ventricular oversensing; Ventricular pacing percentage greater than limit
	On
	On
	2; 4; 6; 8; 10; 12; 14; 16 sec
	2
	1-16
	10; 22 hours
	30 minutes (2 user programmable + discrimination channel) up to 1 minute programmable pre-trigger

Electrograms and Diagnostics		
Stored Electrograms	30 minutes (2 user programmable + discrimination channel), up to 1 minute programmable pre-trigger data per VT/VF electrograms; additional triggers include lead noise detection, non-sustained ventricular oversensing, morphology template updates, atrial episode, PMT termination, PAC response, magnet reversion, noise reversion	
Therapy Summary	Diagram of therapies delivered	
Episodes Summary	Directory listing of up to 60 episodes with access to more details including stored electrograms	
Lifetime Diagnostics	History of bradycardia events and device-initiated charging	
AT/AF Burden Trend	Trend data and counts	
Ventricular HV Lead Impedance	Multi-Vector Trend Data	
Histograms and Trends	Event Histogram; AV Interval Histogram; Mode Switch or AT/AF Duration Histogram; Peak Filtered Atrial Rate during Atrial Arrhythmia Histogram; Atrial Heart Rate Histogram; Ventricular Heart Rate Histogram; AT/AF Burden; Exercise and Activity Trending; V Rates during AMS; DirectTrend [™] reports up to 1 year	
PMT Data	Information regarding PMT detections	
Real-Time Measurements (RTM)	Pacing lead impedances; High-voltage lead impedances; Signal amplitudes	
CorVue [™] Thoracic Impedance	On; Off	
CorVue Thoracic Impedance Threshold	8-18 days	
MRI Settings		
Tachy Therapy	Disabled	
MRI Mode	DOO; VOO; AOO; Pacing Off	
MRI Base Rate	30-100 bpm	
MRI Paced AV Delay	25-120 ms	
MRI Pulse Amplitude	5.0 or 7.5 V	
MRI Pulse Width	1.0 ms	
MRI Pulse Configuration	Bipolar	
MRI Timeout	Off; 3; 6; 9; 12; 24 hours	

MRI SCAN PARAMETERS¹ Lead Model Magnet (Tesla) **RF** Transmit Conditions Scan Region Durata[™] Defibrillation Lead 7120 (lead lengths: 60, 65 cm) 1.5 T / 3 T 7122 (lead lengths: 60, 65 cm) **Optisure**[™] Lead 1.5 T / 3 T LDA220 (lead lengths: 60, 65 cm) Normal LDA210 (lead lengths: 60, 65 cm) Operating Full-body Tendril[™] STS Pacing Lead Mode 1.5 T / 3 T 2088TC (lead lengths: 46, 52 cm) Tendril MRI[™] Lead 1.5 T LPA1200M (lead lengths: 46, 52 cm) UltiPace Pacemaker Lead 1.5 T / 3 T LPA1231 (Lead lengths 46, 52 cm)

^tFor additional information about specific MR Conditional ICDs and leads, including scan parameters, warnings, precautions, adverse conditions to MRI scanning, and potential adverse events, please refer to the Abbott MRI-Ready Systems Manual at <u>medical.abbott/manuals</u>.

Rx Only

Brief Summary: This product is intended for use by or under the direction of a Physician. Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.

Intended Use: The Implantable Cardioverter Defibrillator (ICD) devices are intended to provide ventricular antitachycardia pacing and ventricular cardioversion/defibrillation.

The myMerlinPulse[¬] mobile application is intended for use by people who have an Abbott Medical implanted heart device and access to a mobile device. The app provides remote monitoring capability of the implanted heart device by transmitting information from the patient's implanted heart device to the patient's healthcare provider.

Indications: The ICD devices are indicated for automated treatment of life-threatening ventricular arrhythmias.

In addition, dual chamber ICD devices with the AT/AF detection algorithm are indicated in patients with atrial tachyarrhythmias or those patients who are at significant risk of developing atrial tachyarrhythmias.

MR Conditional ICDs are conditionally safe for use in the MRI environment when used in a complete MR Conditional system and according to instructions in the MRI-Ready Systems manual. Scanning under different conditions may result in severe patient injury, death or device malfunction.

The myMerlinPulse" mobile application is indicated for use by patients with supported Abbott Medical implanted heart devices.

Contraindications: Contraindications for use of the pulse generator system include ventricular tachyarrhythmias resulting from transient or correctable factors such as drug toxicity, electrolyte imbalance, or acute myocardial infarction.

The myMerlinPulse[™] mobile application is contraindicated for use with any implanted medical device other than supported Abbott Medical implanted heart devices.

Adverse Events: Possible adverse events associated with the implantation of the pulse generator system include the following: Arrhythmia (for example, accelerated or induced), Bradycardia, Cardiac or venous perforation, Cardiac tamponade, Cardiogenic shock, Death, Discomfort, Embolism, Endocarditis, Erosion, Exacerbation of heart failure, Excessive fibrotic tissue growth, Extracardiac stimulation (phrenic nerve, diaphragm, pectoral muscle),

ABBOTT

15900 Valley View Court, Sylmar, CA 91342 Tel: +1 818 362 6822 Abbott.com

^w Indicates a trademark of the Abbott group of companies.
¹Indicates a third party trademark, which is property of its respective owner.

© 2024 Abbott. All Rights Reserved. MAT-2400586 v2.0 | Item approved for U.S. only.

Extrusion, Fluid accumulation within the device pocket, Formation of hematomas, cysts, or seromas, Heart block, Hemorrhage, Hemothorax, Hypersensitivity, including local tissue reaction or allergic reaction, Infection, Keloid formation, Myocardial damage, Nerve damage, Occlusion/Thrombus, Pericardial effusion, Pericarditis, Pneumothorax, Pulmonary edema, Syncope, Thrombosis, Valve damage. Complications reported with direct subclavian venipuncture include pneumothorax, hemothorax, laceration of the subclavian artery, arteriovenous fistula, neural damage, thoracic duct injury, cannulation of other vessels, massive hemorrhage and rarely, death. Among the psychological effects of device implantation are imagined pulsing, depression, dependency, fear of premature battery depletion, device malfunction, inappropriate pulsing, shocking while conscious, or losing pulse capability. Possible adverse device effects include complications due to the following: , Abnormal battery depletion, Conductor fracture, Device-programmer communication failure, Elevated or rise in defibrillation/cardioversion threshold, Inability to defibrillate or pace, Inability to interrogate or program due to programmer or device malfunction, Incomplete lead connection with pulse generator, Inhibited therapy including defibrillation and pacing, Inappropriate therapy (for example, shocks and antitachycardia pacing [ATP] where applicable, pacing), Interruption of function due to electrical or magnetic interference, Intolerance to high rate pacing (for example dyspnea or discomfort), Lead abrasion, Lead fracture, Lead insulation damage, Lead migration or lead dislodgement, Loss of device functionality due to component failure, Pulse generator migration, Rise in DFT threshold, Rise in pacing threshold and exit block, Shunting of energy from defibrillation paddles, System failure due to ionizing radiation. Additionally, potential adverse events associated with the implantation of a coronary venous lead system include the following: Allergic reaction to contrast media, Breakage or failure of implant instruments, Prolonged exposure to fluoroscopic radiation, Renal failure from contrast media used to visualize coronary veins. Refer to the User's Manual for detailed intended use, indications, contraindications, warnings, precautions and potential adverse events

No potential adverse events have been identified with use of the myMerlinPulse $\mbox{``}$ mobile application.

